OCT 01, 2019 11:03 AM PDT

Breast Cancer Drug Increases Survival for Prostate Cancer Patients

WRITTEN BY: Carmen Leitch

A clinical trial has shown that a drug used in the treatment of ovarian and breast cancer is better at treating advanced prostate cancer in some men than targeted hormone therapeutics that are currently in use. The study, called the PROfound trial (described in the video), compared the efficacy of olaparib, which is approved for use in breast cancer patients with BRCA mutations, with the drugs abiraterone and enzalutamide, which are hormone treatments used to target prostate cancer tumors carrying dysfunctional DNA repair genes. Olaparib delayed the progression of prostate cancer by about 66 percent in men carrying these faulty genes.

"Our clinical trial shows that olaparib, a pill without the side effects of chemotherapy, is able to target an Achilles' heel in cancer cells. Olaparib is able to kill cancer cells with faulty DNA repair genes while sparing normal cells," explained the co-leader of the trial, Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London.

Men with prostate cancer who had received hormone therapy to treat tumors carrying one of fifteen dysfunctional DNA repair genes in their cells were selected for this study. A gene called ATM, and the well-known genes associated with breast cancer BRCA1 and BRCA2 were some of those genes. For patients with genetic changes in those genes, the amount of time they had before their cancer progressed was lengthened by olaparib treatment; their profession-free survival time was extended from 3.6 months to 7.4 months. Olaparib treatment extended the median overall survival time to 18.5 months from 15 months with hormonal treatment.

This work confirms a study from earlier this year that determined olaparib could double progression-free survival in men with BRCA alterations in their prostate tumor cells.

"Our findings also have wider implications in showing that prostate cancer, like many other cancer types, is really a range of sub-types of disease identifiable by their different arrays of genetic faults. It's essential that we become smarter in the way we treat prostate cancer so that every man gets the treatment that will be of greatest benefit for them," added de Bono.

Wild type human prostate cells from an organoid  / Credit: National Institutes of Health

More follow-up will be needed for these patients to prove that olaparib is a better drug, the researchers noted. The drug also had higher rates of adverse impacts compared to the hormone therapies. About 8.5 percent of patients cannot tolerate the abiraterone or enzalutamide, while 16.4 percent of patients had to stop taking olaparib. The olaparib treatment also goes on for about twice as long.

This study has shown that there are subtypes of prostate cancer, just as there are with lung and breast cancer. It also demonstrates that assessing tumor cell genomes can provide important information that can help determine which treatment is best for a patient.

"This study is a powerful demonstration of the potential of precision medicine to transform the landscape for patients with the commonest of male cancers. I hope that within the next couple of years, olaparib will become the first precision medicine to become available as a standard treatment for men with prostate cancer," said de Bono.

Learn more about BRCA in different types of tumors from the video.


Sources: AAAS/Eurekalert! via Institute of Cancer Research

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 14, 2019
Cell & Molecular Biology
NOV 14, 2019
Scientists debunk evidence of a single "gay gene"
Study reveals that specific locations within the genome are associated with homosexual behavior, but not a particular "gay gene" as was popular belief....
NOV 14, 2019
Cell & Molecular Biology
NOV 14, 2019
Insight Into the Epigenetic Mechanisms Controlling Cellular Identity
Every cell type has to carefully control which genes are expressed, and new research has learned more about that process....
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
How Liquid Biopsies Can Teach Us About Cancer Drug Resistance
Cancer patients often endure challenging treatment courses to shrink their tumors, but the tumors can make a powerful comeback....
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
Gene-Editing Breakthrough for Cervical Cancer
Researchers at the The Menzies Health Institute Queensland have found a way to use gene therapy CRISPR-Cas9 to treat cervical cancer. The first treatment o...
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
A Cancer-Promoting Mutation is Found in 'Junk' DNA
A huge amount of our genome does not code for protein, but it can impact physiology in other ways....
NOV 14, 2019
Genetics & Genomics
NOV 14, 2019
Learning More About Changes in Cancer Cell Identity
Cancer cells can change their identity and can take on new functions and characteristics, which is often rooted in epigenetic alterations....
Loading Comments...